News - Herceptin, Oncology

Filter

Current filters:

HerceptinOncology

Popular Filters

1 to 25 of 32 results

EMA says that vials of falsified Herceptin have been identified

EMA says that vials of falsified Herceptin have been identified

16-04-2014

The European Medicines Agency says it has been informed that vials of Swiss drug major Roche’s blockbuster…

EuropeHealthcareHerceptinOncologyPharmaceuticalRegulationRoche

Factors driving oncologists’ prescribing decisions for HER2-positive breast cancer patients

Factors driving oncologists’ prescribing decisions for HER2-positive breast cancer patients

28-03-2014

Efficacy, more than any other factors, drives oncologists’ prescribing of targeted therapies for breast…

AfinitorbuparlisibGlaxoSmithKlineHerceptinMarkets & MarketingNovartisOncologyPerjetaPharmaceuticalRocheTykerb

Roche sues Biocon and Mylan over Herceptin biosimilar; US puts pressure on India over IP

Roche sues Biocon and Mylan over Herceptin biosimilar; US puts pressure on India over IP

10-02-2014

Swiss pharma major Roche’s Indian subsidiary has sued Bangalore-based Biocon and US generics firm Mylan…

Asia-PacificBioconBiosimilarsCanmabHerceptinHertrazIndiaLegalMylan LaboratoriesOncologyPatentsPharmaceuticalRegulationRoche

Mylan debuts Hertraz, first Herceptin biosimilar, in India

Mylan debuts Hertraz, first Herceptin biosimilar, in India

03-02-2014

US generics major Mylan has launched the world's first trastuzumab biosimilar in India. The product,…

Asia-PacificBioconBiosimilarsGenericsHerceptinHertrazIndiaMarkets & MarketingMylan LaboratoriesOncologyRoche

MAb market for gastric and esophageal cancer expected to double by 2019

MAb market for gastric and esophageal cancer expected to double by 2019

18-01-2014

Due to favorable market conditions in terms of US pricing structures and the anticipated approval of…

BiotechnologyHerceptinMarkets & MarketingOncologyRoche

Celltrion’s trastuzumab biosimilar, Herzuma, approved in South Korea

16-01-2014

South Korean biopharmaceutical firm Celltrion has received approval for its cancer treatment biosimilar…

Asia-PacificBiosimilarsCellTrionGenericsHerceptinHerzumaOncologyRegulationRoche

Mylan-Biocon Herceptin biosimilar gets first Indian approval

Mylan-Biocon Herceptin biosimilar gets first Indian approval

26-11-2013

US generic major Mylan says that its partner, India-based biotechnology firm Biocon has received approval…

Asia-PacificBioconBiosimilarsGenericsHerceptinHertrazMylan LaboratoriesOncologyRegulationRoche

More highlights from European Cancer Congress from Boehringer and Roche

More highlights from European Cancer Congress from Boehringer and Roche

30-09-2013

Roche presented new results from a trial of an investigational antibody which have shown encouraging…

Boehringer IngelheimEuropeHerceptinnintedanibOncologyPharmaceuticalResearchRoche

Roche's subcutaneous Herceptin injection approved for use in UK

Roche's subcutaneous Herceptin injection approved for use in UK

24-09-2013

From today HER2-positive breast cancer patients in the UK could benefit from a faster, more efficient…

EuropeHerceptinLicensingOncologyPharmaceuticalRoche

Roche's new timesaving formulation of Herceptin approved in Europe

02-09-2013

Swiss pharma major Roche (ROG: SIX) revealed this morning (September 2) that a new injectable (subcutaneous)…

BiotechnologyEuropeHerceptinOncologyPharmaceuticalRegulationRoche

US firms establish strategic partnership around biosimilars

06-08-2013

Privately-held Oncobiologics has formed a broad strategic partnership with fellow USA-based inVentiv…

AvastinBiotechnologyErbituxGenericsHerceptinHumiraImmunologicalsinVentive HealthOncobiologicsOncologyProductionResearchRituxan

Roche hopes Kadcyla will replace revenue lost by Herceptin patent expiry

02-08-2013

Swiss drug major Roche (ROG: SIX) could be hit by biosimilar versions of its breakthrough HER2-positive…

EuropeFinancialHerceptinKadcylaOncologyPharmaceuticalRoche

Study confirms everolimus can overcome trastuzumab resistance in HER-2 positive early breast cancer

03-05-2013

A study that aimed to understand how the cancer drug everolimus helps overcome the resistance breast…

AfinitoreverolimusHerceptinNovartisOncologyPharmaceuticalResearchRochetrastuzumab

Russia's Biocad plans to produce high-tech drugs in Brazil

19-03-2013

Biocad, one of Russia's leading biotechnology companies, plans to launch production of several of its…

AvastinBiocadBiotechnologyGenericsHerceptinMabTheraOncologyProductionRocheSouth America

HER2-positive breast cancer patients prefer faster subcutaneous administration of Herceptin to IV

15-03-2013

Results from the PrefHer (Patient Preference for Subcutaneous (SC) versus Intravenous (IV) Herceptin)…

EuropeFinancialHealthcareHerceptinOncologyPharmaceuticalRegulationRoche

BRIC countries' breast cancer market to see 8% annual growth to 2017

14-02-2013

The market for breast cancer therapies in the BRIC countries (Brazil, Russia, India and China) will grow…

GlaxoSmithKlineGlobalHerceptinMarkets & MarketingOncologyPharmaceuticalRocheTykerb

San Antonio breast cancer meeting highlights

10-12-2012

There was mixed news coming out of the San Antonio Breast Cancer Symposium (SABCS), which concluded on…

AvastinBiotechnologyEisaiGenentechHerceptinOncologyPerjetaPharmaceuticalResearchRoche

Pfizer and Roche hope to score with ESMO presentations, notes GlobalData

25-09-2012

The European Society for Medical Oncology (ESMO) will kick off its 2012 annual meeting on Friday, September…

BiotechnologyHerceptinOncologyPfizerPharmaceuticalResearchRocheXalkori

GlaxoSmithKline pulls sNDA for Tykerb plus Herceptin; Watson/Actavis update

13-07-2012

UK pharma giant GlaxoSmithKline (LSE: GSK) revealed yesterday that it has withdrawn a supplemental New…

ActavisGenericsGlaxoSmithKlineHerceptinMergers & AcquisitionsNorth AmericaOncologyPharmaceuticalRegulationRocheTykerbWatson Pharmaceuticals

75% of US oncologists prescribe Pfizer's Xalkori just 10 months after the drug's launch

21-06-2012

US oncologists surveyed by advisory firm Decision Resources say they prescribe drugs behemoth Pfizer's…

GlaxoSmithKlineHerceptinMarkets & MarketingNorth AmericaOncologyPfizerPharmaceuticalResearchRocheTarcevaTykerbXalkori

1 to 25 of 32 results

Company Spotlight

Eleven Biotherapeutics

Eleven Biotherapeutics

Back to top